ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

America ’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property protections, public sector investments in education and basic sciences, and a reliable rule of law. However, as PhRMA President and CEOSteven J. Ubl notes in Real Clear Health, other countries put up trade-related barriers that weaken U.S. competitors and benefit their own domestic industries.
Source: The Catalyst - Category: Pharmaceuticals Tags: Patents Intellectual Property trade Source Type: news